Aprepitant - Generic Drug Details

What are the generic sources for aprepitant and what is the scope of patent protection?

Aprepitant is the generic ingredient in four branded drugs marketed by Glenmark Speclt, Sandoz, Torrent, MSD, Heron Theraps Inc, Mylan, and Msd Merck Co, and is included in eight NDAs. There are fifteen patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Aprepitant has fifty-seven patent family members in thirty-seven countries.

There are twenty-six drug master file entries for aprepitant. Seven suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for aprepitant

International Patents:	57
US Patents:	15
Tradenames:	4
Applicants:	7
NDAs:	8
Drug Master File Entries:	26
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	87
Clinical Trials:	186
Patent Applications:	6,875
Drug Prices:	Drug price trends for aprepitant
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for aprepitant
What excipients (inactive ingredients) are in aprepitant?	aprepitant excipients list
DailyMed Link:	aprepitant at DailyMed

See drug prices for aprepitant

Recent Clinical Trials for aprepitant

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Montefiore Medical Center	PHASE4
Centre hospitalier de l'Universit de Montral (CHUM)	PHASE3
Rabin Medical Center	PHASE1

See all aprepitant clinical trials

Generic filers with tentative approvals for APREPITANT

Applicant	Application No.	Strength	Dosage Form
		130MG/18ML	INJECTION, EMULSION
		130MG/18ML (7.2MG/ML)	INJECTABLE;INTRAVENOUS

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for aprepitant

Drug Class	Substance P/Neurokinin-1 Receptor Antagonist
Mechanism of Action	Cytochrome P450 2C9 Inducers Cytochrome P450 3A4 Inducers Cytochrome P450 3A4 Inhibitors Neurokinin 1 Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for aprepitant

A04AD	Other antiemetics
A04A	ANTIEMETICS AND ANTINAUSEANTS
A04	ANTIEMETICS AND ANTINAUSEANTS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for APREPITANT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
APONVIE	Intravenous Emulsion	aprepitant	32 mg/4.4 mL	216457	1	2023-11-07
CINVANTI	Intravenous Emulsion	aprepitant	130 mg/18 mL	209296	1	2022-04-29
EMEND	for Oral Suspension	aprepitant	125 mg/Kit	207865	1	2016-11-23
EMEND	Capsule	aprepitant	40 mg, 80 mg and 125 mg	021549	1	2008-11-03

US Patents and Regulatory Information for aprepitant

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Merck Co	EMEND	aprepitant	FOR SUSPENSION;ORAL	207865-001	Dec 17, 2015		RX	Yes	Yes	8,258,132		Y
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-001	Mar 26, 2003	AB	RX	Yes	No	8,258,132		Y
Heron Theraps Inc	APONVIE	aprepitant	EMULSION;INTRAVENOUS	216457-001	Sep 16, 2022		RX	Yes	Yes	11,878,074
Heron Theraps Inc	APONVIE	aprepitant	EMULSION;INTRAVENOUS	216457-001	Sep 16, 2022		RX	Yes	Yes	10,500,208		Y
Heron Theraps Inc	CINVANTI	aprepitant	EMULSION;INTRAVENOUS	209296-001	Nov 9, 2017		RX	Yes	Yes	12,290,520		Y
Heron Theraps Inc	APONVIE	aprepitant	EMULSION;INTRAVENOUS	216457-001	Sep 16, 2022		RX	Yes	Yes	12,115,254		Y

Expired US Patents for aprepitant

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-003	Jun 30, 2006	7,214,692
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-002	Mar 26, 2003	6,048,859
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-003	Jun 30, 2006	5,719,147
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-001	Mar 26, 2003	7,214,692
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-003	Jun 30, 2006	5,145,684
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-003	Jun 30, 2006	6,235,735

EU/EMA Drug Approvals for aprepitant

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp & Dohme B.V.	Emend	aprepitant	EMEA/H/C/000527Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics).Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years.Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy.	Authorised	no	no	no	2003-11-11

International Patents for aprepitant

Country	Patent Number	Title	Estimated Expiration
China	100352443
Hungary	230736	Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist
China	106852118
Japan	6741655
Israel	162296	הרכב רוקחי נאנו-חלקיקי של אנטגוניסטלרצפטור הקושר תכיקינין (Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist)
Norway	336943

Supplementary Protection Certificates for aprepitant

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0748320	08C0019	France		PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
0734381	PA2004002	Lithuania		PRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111
0734381	PA2004002,C0734381	Lithuania		PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111
0748320	SPC/GB08/021	United Kingdom		PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111
0734381	3/2004	Austria		PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
0734381	04C0010	France		PRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111

Aprepitant Market Dynamics and Financial Trajectory: Revenue, Demand Drivers, Pricing, and Competitive Position

Last updated: April 23, 2026

Aprepitant (oral/IV NK1 receptor antagonist) has a mature antiemetic market presence driven by chemotherapy-induced nausea and vomiting (CINV) protocols and guideline adherence. Commercial performance has shifted from broad early adoption toward life-cycle management across fixed-dose combinations, expanded regimen mix, and competitive pressure from generics and therapeutic alternatives.

What drives aprepitant demand and market access?

1) Clinical demand is anchored in CINV guideline algorithms

Aprepitant is used in multi-day and single-day CINV regimens, typically as part of NK1-receptor antagonist-based combinations with 5-HT3 receptor antagonists and corticosteroids. The commercial demand profile maps to chemotherapy utilization and the share of patients treated with emetogenic regimens where NK1-based prophylaxis is recommended.

2) Formulation and regimen fit affect payer adoption

Market access depends on formulary placement for:

• NK1 antagonist component in CINV pathways
• Route of administration for institutional workflows (IV vs oral), especially where outpatient infusion centers manage day-1 IV and subsequent oral dosing

3) Switching risk is structural

Aprepitant’s market is exposed to:

• Generic substitution after exclusivity expiry
• Therapeutic substitution from other CINV agents and evolving guideline preferences
• Biosimilar-like dynamics are not relevant, but small-molecule substitution and tender-led procurement are

How has the competitive landscape shaped pricing and share?

Generic entry and margin compression

Aprepitant’s trajectory follows the typical small-molecule antiemetic pattern:

• Early premium pricing during brand exclusivity
• Then price erosion post-generic entry
• Then revenue stabilization at lower price points driven by persistence of protocol usage and remaining brand differentiators (packaging, clinical familiarity, and administered regimen logistics)

Competitive alternatives

The CINV market includes multiple classes that can win specific patient or provider preferences:

• Other NK1 receptor antagonists and regimen structures
• 5-HT3 antagonists, dexamethasone regimens, and risk-adapted approaches
• Newer agents that can shift prescriber behavior by regimen simplicity, dosing convenience, or reimbursement economics

Net effect: brand unit demand often remains resilient due to guideline reinforcement, but realized revenue trends decline due to price compression.

What is the likely revenue trajectory across the life cycle?

Revenue path: exclusivity peak to stabilized low-price base

Aprepitant’s financial trajectory is best understood in two phases:

1. Exclusivity and adoption phase: Revenue grows with clinical adoption as NK1-based prophylaxis becomes embedded in standard CINV regimens.
2. Post-exclusivity stabilization phase: Units often persist, but realized revenue declines with generic entry and procurement-driven pricing.

Real-world revenue mechanics

In mature oncology supportive-care markets:

• Volume stays tied to chemotherapy mix and CINV prophylaxis penetration.
• Revenue follows a “price-first” adjustment after generic substitution, with volume declines often secondary unless substitution is aggressive.

What do global patent and exclusivity events imply for market timing?

Key patent framework (high-level)

Aprepitant is protected by a network of composition-of-matter and method/regimen-related intellectual property plus regulatory exclusivities in multiple jurisdictions. The commercial timing is typically governed by:

• Composition-of-matter expiration
• Secondary patents affecting formulations or specific dosing regimens
• Regulatory exclusivity (where applicable)

Practical implication

Once the legal barrier falls, price falls quickly in tender and national formulary systems. Aprepitant’s mature status means current market dynamics are primarily driven by:

• Generic share
• Contracting and pharmacy benefit manager (PBM) dynamics
• Continued protocol usage

Where does financial performance concentrate across channels?

1) Hospital and infusion center channels

Supportive oncology is procurement-heavy. Institutional formularies and conversion decisions are driven by:

• Tender economics
• Inventory and IV-to-oral switching workflow
• Budget impact analysis for antiemetic bundles

2) Specialty pharmacy and outpatient dispensing

Outpatient oncology typically relies on pharmacy networks and prior authorization patterns less than hospitals, but PBM contracting still drives net pricing:

• Brand vs generic tier placement
• Copay and coverage rules
• Step therapy where payer policies exist

3) International differences

Aprepitant market outcomes vary by:

• Date of generic approvals and local launches
• Reimbursement systems and tender regimes
• Local guideline adoption patterns

What financial outcomes typically follow for aprepitant brands?

Brand revenue tends to decline faster than unit demand after generics

For a mature antiemetic, the financial signature after generic introduction typically shows:

• Lower net sales due to steep price erosion
• Better-than-expected volume stability (protocol continuation)
• Increased reliance on remaining differentiation levers (pack size, physician familiarity, institutional contracting)

Pipeline and lifecycle tools

Companies usually respond with:

• Line extensions via dosing/formulation improvements
• Evidence packages supporting specific risk categories
• Marketing focus on regimen adherence and clinician trust

Market dynamics by segment: acute, delayed, and multi-day emesis control

Aprepitant’s clinical role extends across CINV phases (notably delayed nausea/vomiting in multi-day regimens). That matters for commercial performance because:

• Delayed CINV prophylaxis persistence is protocol-driven
• Multi-day regimen completion affects total patient exposure and repeat dispensing
• Any regimen redesign that reduces NK1 antagonist exposure can affect unit demand, even if initial prophylaxis remains

How does payer and reimbursement policy change realized pricing?

Net price compression mechanisms

Realized pricing for branded supportive oncology drugs commonly declines through:

• Formulary tier reclassification
• PBM rebate pressures
• Contracting tied to market share and generic parity
• Reference pricing in some reimbursement systems

Consequence for financial trajectory

Net sales usually track:

• A steep decline after generic entry
• A longer plateau at a lower price level if generic supply stabilizes and procurement locks in routine CINV pathway usage

What do investors and R&D teams look for now in aprepitant’s trajectory?

Key indicators

• Generic share in major markets (drives price floor)
• Uptake of protocol refinements that use NK1 antagonists in narrower or broader patient segments
• Tender price indexes in hospital systems
• Net-to-gross trends for the brand (rebates and contracting)

Commercial durability

Even as pricing declines, NK1 antagonists often retain a role because CINV prevention is a standard-of-care objective and chemotherapy providers face accountability for emesis outcomes.

---

Key Takeaways

• Aprepitant demand is anchored to CINV prophylaxis algorithms where NK1 antagonists remain part of standard multi-drug regimens.
• The financial trajectory is dominated by post-exclusivity pricing compression from generic entry, with unit volume typically more resilient than net pricing.
• Hospital procurement and PBM contracting determine realized price more than headline list pricing.
• Competitive alternatives influence share by regimen convenience and payer preference, but guideline reinforcement tends to sustain baseline NK1 antagonist utilization.
• Current market dynamics are best read through tender-led pricing, generic penetration, and protocol stability across delayed and multi-day emesis phases.

FAQs

1. Is aprepitant primarily driven by oncology supportive care rather than broader indications?
   Yes. Commercial demand is most consistently tied to CINV prevention within chemotherapy supportive-care protocols.

2. What happens to revenue after generic entry for aprepitant?
   Net sales usually decline faster than units because price compression drives revenue erosion, while protocol-driven use can keep volume relatively steadier.

3. Which channel most affects aprepitant’s realized pricing?
   Hospital and infusion center procurement is typically the largest lever, followed by PBM and specialty pharmacy contracting.

4. Does regimen structure materially affect commercial performance?
   Yes. Use across delayed and multi-day phases increases total exposure; any shift that narrows NK1 antagonist coverage can reduce total dosing.

5. What competitive forces matter most for aprepitant today?
   Generic competition and tender/PBM contracting, plus therapeutic alternatives that can alter prescribing behavior within specific emetogenic risk categories.

References

[1] FDA. Emend (aprepitant) prescribing information. U.S. Food and Drug Administration. (Accessed via FDA labeling database).
[2] National Comprehensive Cancer Network (NCCN). Guidelines for Antiemesis. NCCN Clinical Practice Guidelines in Oncology.
[3] EMA. Product information for aprepitant-containing medicines. European Medicines Agency.